EDAP TMS S.A. (FOCL)
FOCLNASDAQ-GMBiotechnology: Electromedical & Electrotherapeutic Apparatus
$3.50
-0.0200 (-0.57%) today
At the close, Nov 10, 4:00 PM ET. After hours $3.50 –
- Market cap
- $165.27m
- P/E
- –
- EPS, last 4 quarters
- $-0.9000
- Dividend yield
- –
- Day range
- $3.44 to $3.56
- 52-week range
- $1.82 to $6.40
- Average volume
- 69.7k
- Previous close
- $3.52
Analysts
3 coveringHold2 buy, 1 hold, 0 sell
Targets a year out average $7.33, +109.4% from here
Earnings
next estimate $-0.1600Next report
Dec 2025
-56.3%
Mar 2026
-9.1%
Jun 2026
-20.0%
Sep 2026
+5.6%
estimate reported, and the surprise
Financials
| Quarter | Mar 2026 | Jun 2026 |
|---|---|---|
| Revenue | $17.81m | $6.98m |
| Gross profit | $8.15m | $5.15m |
| Operating income | -$7.37m | -$8.69m |
| Net income | -$9.08m | -$14.49m |
News
8 latest- FocalTherics Reports Lower Q3 Loss Of $4 Mln; Shares Drop 21% As Guidance Narrowed RTTNews · 3 days ago
- EDAP TMS (FOCL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- FocalTherics Q3 Earnings Call HighlightsMarketBeat · 5 days ago
- FocalTherics (FOCL) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 18, 2026
- FocalTherics Q2 Earnings Call HighlightsMarketBeat · Aug 13, 2026
- FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down RTTNews · Aug 12, 2026
- FocalTherics (FOCL) Surges 6.2%: Is This an Indication of Further Gains?Zacks · Aug 5, 2026
- Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera RTTNews · Jun 19, 2026
The company
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- edap-tms.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.